Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.8461
-0.0139 (-1.62%)
Apr 2, 2025, 1:13 PM EDT - Market open

Citius Oncology Cash Flow Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Dec '24 Sep '24 Sep '23 Sep '22
Net Income
-23.08-21.15-12.7-10.87
Stock-Based Compensation
7.397.51.97-
Other Operating Activities
0.70.580.581.15
Change in Inventory
-8.25-2.13--
Change in Accounts Payable
5.672.421.20.18
Change in Other Net Operating Assets
17.712.918.969.53
Operating Cash Flow
0.130.13--
Sale (Purchase) of Intangibles
-5-5--
Investing Cash Flow
-5-5--
Long-Term Debt Issued
-3.8--
Net Debt Issued (Repaid)
3.83.8--
Other Financing Activities
1.071.07--
Financing Cash Flow
4.874.87--
Net Cash Flow
00--
Levered Free Cash Flow
-1.26-1.944.55-
Unlevered Free Cash Flow
-1.26-1.944.55-
Change in Net Working Capital
-10.34-8.42-10.16-
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q